Basiliximab (trade name Simulect) is a
chimeric mouse-human monoclonal
antibody to the α chain (
CD25) of the
IL-2 receptor of
T cells. It is used to prevent
rejection in
organ transplantation, especially in
kidney transplants.
Uses
Basiliximab is an
immunosuppressant agent used to prevent immediate
transplant rejection in people who are receiving kidney transplants, in combination with other agents.
[MedlinePlus. Last Revised - June 15, 201]
Basiliximab Injection
/ref> It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.
Mechanism of action
Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies
An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein used by the immune system to identify and neutralize foreign objects such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the ...
, which would bind to the transplanted organ and stimulate an immune response against the transplant.[Basiliximab label]
/ref>
Chemistry
It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[
]
History
It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.
See also
* Daclizumab
References and notes
{{Interleukin receptor modulators
Immunosuppressants
Novartis brands